ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1575

Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis

Jason Springer1, Tanaz Kermani2, Dianne Shaw3, Kalen Larson4, Cristina Burroughs5 and Peter Merkel6, 1Vanderbilt University Medical Center, Nashville, TN, 2University of California Los Angeles, Los Angeles, CA, 3Vasculitis Foundation, Chapel Hill, NC, 4Vasculitis Foundation, Kansas City, MO, 5University of South Florida, Tampa, FL, 6University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2022

Keywords: longitudinal studies, Vasculitis, Vasculitis, Cutaneous

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Urticarial vasculitis is a markedly rare disease, with an annual incidence of < 1 per million. Hypocomplementemia is associated with systemic features and a worse prognosis. The purpose of this study is to describe and validate this international cohort based on patient reported data.

Methods: Participant enrollment was via a prospective, international, internet-based longitudinal vasculitis registry. Participants with a self-reported diagnosis of urticarial vasculitis were included. Enrollment was from November 2014 to February 2022. On-line standardized forms included data on disease manifestations, diagnostic testing and treatment. Responses of “I don’t know” or missing responses were excluded. The 2012 Chapel Hill Consensus Conference (CHCC) definition of urticarial vasculitis was felt met if patients reported a) biopsy showing vasculitis, and b) any of the following: kidney involvement, joint involvement, obstructive lung disease, or ocular involvement. Fisher exact test was used to make comparisons between groups.

Results: Data from 102 participants with a self-reported diagnosis of urticarial vasculitis was used for this analysis. 92 (90%) were female. Mean age at onset of symptoms was 40.5 years old (SD 15.0) and at diagnosis was 44.1 years old (SD 13.2). All patients reported a hive-like rash. 90% (89/99) reported having a skin biopsy, of which 87% (77/89) reported the skin biopsy showed vasculitis. 84 patients (82%) reported that their diagnosis was based on the biopsy results (Table 1). 69% (37/54) reported a history of obstructive lung disease. Table 2 lists other reported manifestations/symptoms. 53% (31/59) report either a low C3 or C4. 74% (23/31) of those reporting low C3 or C4 met the CHCC definition for hypocomplementemic urticarial vasculitis. Systemic manifestations were more common in those reporting low C3 or C4 compared to those reporting normal C3 and C4 (90% vs 68%, p=0.05) (Table 2). 51% (34/67) report a positive anti-nuclear antibody. The physician specialty reported to manage the UV included: rheumatology 52 (51%), primary care 35 (34%), dermatologist 26 (25%), and Allergist/Immunologist 16 (16%). The medications most frequently reported used by patients are listed in Table 3.

Conclusion: The diagnosis of urticarial vasculitis is clinicopathological, based on both the clinical manifestation of urticaria and histologic confirmation of small-vessel vasculitis. All patients in this cohort reported urticarial rashes, the majority reported a skin biopsy showing vasculitis, and the manifestations of disease are consistent with physician-reported cohorts. This cohort has an overrepresentation of participants with more severe disease, possibly reflecting a higher propensity of such patients to participate in internet-based research. Internet-based cohorts, based on patient reported data, are means for the future conduct of large clinical trials in extremely rare diseases, such as urticarial vasculitis.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Springer, Chemocentryx; T. Kermani, None; D. Shaw, None; K. Larson, None; C. Burroughs, None; P. Merkel, AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Neutrolis, Takeda, CSL Behring, Dynacure, EMDSerono, Immagene, Jannsen, Kiniksa, Magenta, Novartis, Pfizer, Q32, Regeneron, Sparrow, Eicos, Electra, Kyverna, UpToDate.

To cite this abstract in AMA style:

Springer J, Kermani T, Shaw D, Larson K, Burroughs C, Merkel P. Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/characteristics-of-an-internet-based-international-cohort-of-patients-with-a-self-reported-diagnosis-of-urticarial-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristics-of-an-internet-based-international-cohort-of-patients-with-a-self-reported-diagnosis-of-urticarial-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology